FDA
-
-
-
-
-
-
-
FDA approves expanded HYMPAVZI use for hemophilia patients with inhibitors
-
-
-
-
-
-
-
Pfizer's LORBRENA shows 55% seven-year survival without progression
-
-
-
-
-
-
-
Arvinas and Pfizer sell VEPPANU rights to Rigel for $85 million upfront
-
-
-
-
-
-
-
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
Pfizer's TALZENNA combination shows progress against prostate cancer
-
-
-
-
-
-
-
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
-
-
-
-
-
-
-
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
-
324,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

